CSF1R and B-cell chronic lymphocytic leukemia: Indeed, in B-cell CLL, CSF1R inhibition with a JAK2/FLT3 inhibitor, pacritinib was associated with significant depletion of TAMs and consequently inhibited leukemic cell survival [75].